Oral Polio Vaccine to Protect Against COVID-19: Out of the Box Strategies?

Melanie Malave Sanchez, Paul Saleeb, Shyam Kotttilil, and Poonam Mathur

Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA

The global coronavirus disease 2019 (COVID-19) pandemic has raised significant concerns of developing rapid, broad strategies to protect the vulnerable population and prevent morbidity and mortality. However, even with an aggressive approach, controlling the pandemic has been challenging, with concerns of emerging variants that likely escape vaccines, nonadherence of social distancing/preventive measures by the public, and challenges in rapid implementation of a global vaccination program that involves mass production, distribution, and execution. In this review, we revisit the utilization of attenuated vaccinations, such as the oral polio vaccine, which are safe, easy to administer, and likely provide cross-protection against respiratory pathogens. We discuss the rationale and data supporting its use and detail description of available vaccines that could be repurposed for curtailing the pandemic.

Keywords. immunity; nonspecific effect; oral polio vaccine; SARS-CoV-2; vaccines.

The global coronavirus disease 2019 (COVID-19) pandemic has forced the medical community to explore every possible solution to slow transmission, with the hope that lives will eventually return to normal. There are growing concerns from a public health perspective given ongoing challenges regarding vaccine equity, production, and distribution. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants also threaten to be more transmissible and escape from vaccine-acquired immunity complicated by continued noncompliance with social distancing and disparities among infection control and mitigation strategies between states.

While public health measures, including vaccination against COVID-19, are in full force, alternative therapeutic and methods of protection against infection are being studied and developed. One underexplored option to combat COVID-19 is OPV as an agent to prime the immune system and confer protection against other infections warrant a reexamination of this strategy.

DISCOVERY OF THE NONSPECIFIC EFFECTS OF OPV

In the 1950s, Voroshilova proposed that nonpathogenic enteroviruses were useful in the eradication of pathogenic enteroviruses. This finding was supported by the observation that the immunogenic effects of OPV were attenuated by the nonpoliomyelitis enteroviruses that colonized the gastrointestinal (GI) tract [2]. Subsequent studies have explored the effects of live enterovirus vaccines (LEV) on generating nonspecific immune responses, including an increase of endogenous interferon inducers, T-cell lymphocytes, and overall cellular immunity. In Moscow and Kharkov, large epidemiologic surveys were performed with 6131 children that demonstrated LEV-4 and LEV-7 nonreactogenicity and vaccine safety [2]. The proven safety of LEVs prompted the Vaccine and Sera Committee of the USSR Ministry of Health to permit studies assessing the potential prevention of influenza and acute respiratory disease of up to 320 000 participants with the use of LEVs during the 1960s. Some of these studies demonstrated that LEV 4 and LEV 7 decreased cytopathic agents in the GI tract 4-fold from 29.3% to 7.7% after vaccination [2]. Incidentally, there was also an associated decrease in isolated infections from influenza, parainfluenza,
respiratory syncytial virus (RSV), adenovirus, and herpesviruses [2]. Additional controlled trials conducted in the former USSR during the influenza seasons of 1968–1971 demonstrated a decreased incidence of influenza and acute respiratory infections (ARIs) in individuals who had received OPV 1–3 and LEV 4, 7 [3–5]. Chumakov et al. (1992) analyzed the results of these controlled trials and found that 60 065 (69.8%) individuals who received the oral Sabin type 1 and 2 vaccines had an average 3.8-fold decrease in acute respiratory infections when compared with 25 924 (30.1%) individuals who were unvaccinated [6]. They also observed that the decrease in incidence of influenza and other respiratory infections was significantly higher in oral Sabin vaccine recipients than influenza vaccine recipients (an analysis for $P$ value was not made) [6]. LEV 4, 7 decreased the incidence rate of ARI by 2.6-fold, an effect similar to that of influenza vaccines. These findings led to the hypothesis that LEV and OPV may offer protection against other viral infections.

**ADDITIONAL EVIDENCE FOR THE NONSPECIFIC EFFECT OF VACCINES**

Recent studies have added to the growing evidence that vaccines may offer nonspecific protection against infections. A randomized controlled trial done in Guinea-Bissau looked at the effect of OPV at birth (OPV0) on infant mortality [7]. They enrolled 7012 neonates, of whom 3495 were randomized to the Bacillus Calmette-Guérin (BCG) group (intervention) and 3517 to the BCG and OPV0 group (standard of care). At 1-year follow-up, there were 87 deaths in the BCG arm and 73 in the BCG + OPV0 arm (overall hazard ratio [HR], 0.83). Irrespective of gender, BCG + OPV0 was associated with lower mortality compared with BCG alone [7]. In addition, no incident polio cases were identified during this trial period, indicating that the nonspecific effects of the vaccine could not be explained by decreasing polio cases. Andersen et al. (2020) analyzed 17 national OPV campaigns and examined mortality rates in children between 1 day and 3 years of age. Mortality was lower after OPV-only campaigns, with an adjusted mortality rate ratio (MRR) of 0.75 (95% CI, 0.67–0.85) [8]. Additional OPV campaigns reduced mortality further by 14% [8].

In 2015, Sorup et al. conducted a retrospective cohort study in Denmark and investigated the admission rate of children due to infectious diseases depending on whether the most recent vaccine they had received was OPV, DTaP-IPV-Hib (diphtheria-tetanus-acellular pertussis–inactivated polio virus–Haemophilus influenzae type b), or MMR (measles, mumps, rubella). They found that when OPV was the most recent vaccine, there was a lower rate of admission for all type of infections—mostly lower respiratory tract infections—when compared with DTaP-IPV-Hib as the most recent vaccine [9]. They also observed that admission rates were lower when MMR was the most recent vaccine when compared with DTaP-IPV-Hib, but there was no statistical difference between OPV and MMR when either was given most recently. A similar study was performed in the United States using the MarketScan US Commercial claims database to evaluate the risk of hospital admission due to nontargeted infections (NTIs) in 311 663 children aged 16–24 months, depending on the last vaccine administered [10]. The study found that the risk of hospitalization from nontargeted infections was reduced in those who received a live vaccine vs an inactivated vaccine alone (HR, 0.50; 95% CI, 0.43–0.57). Similar to the findings by Sorup et al., the biggest reduction in NTIs was for lower and upper respiratory tract infections when using live vaccines. In children who received concomitant live and inactivated vaccines, the reduction in NTIs was less significant (HR, 0.78; 95% CI, 0.67–0.91); therefore, the investigators concluded that concomitant use of live and inactivated vaccines may have a “diluted” effect compared with live vaccines, but the effect is still present [10].

Other live vaccines have also demonstrated mortality benefit. The WHO performed a systematic review and found that BCG had a mortality benefit in children vaccinated at different ages [11, 12]. The effect was lower if the child had been vaccinated at an older age [11]. Investigators in Guinea-Bissau found a reduction in mortality in infants who had a scar after BCG vaccination, attributed to BCG vaccine–nonspecific protection [13, 14]. Prentice et al. (2021) performed an investigator-blind randomized controlled trial with 560 participants who were assigned to BCG at birth (n = 280) or at age 6 weeks (n = 280). They found that BCG vaccination at birth protected the participants against nontuberculous infectious diseases during the neonatal period [15]. The measles vaccine has also demonstrated a mortality benefit unexplained by preventing measles infection alone [11] and a higher mortality benefit in girls [11, 16–19]. Aaby et al. (2010) performed a randomized controlled trial to evaluate if a 25% difference in mortality existed between children aged 4.5 months and 3 years of age after vaccination with the Edmonston-Zagreb measles vaccine at 4.5 months and 9 months, compared with the standard in Guinea-Bissau of 1 dose at 9 months of age. They randomized 6648 children after their 3 doses of diphtheria, tetanus, pertussis vaccine into 3 groups: Edmonston-Zagreb measles vaccine at 4.5 and 9 months of age (group A), Edmonston-Zagreb measles vaccine at 9 months of age only (group B), and Schwarz measles vaccine at 9 months of age only (group C) [17]. They found that a 2-dose measles vaccination was associated with a 22% reduction in all-cause mortality. They confirmed that prevention of measles infection only explained a small portion of the effect on overall mortality [17]. The nonspecific protective effects may exist in all live vaccines, but this requires further research (Table 1).
| Characteristics of Live Attenuated Vaccines |
|---------------------------------------------|
| **Cost [35]** | Repeat administration [36] | Induction of innate immunity [21, 37] | Mucosal immunogenicity | Rare complication | Adverse events | Contraindication | Combination vaccines in USA [36] | Route [36] | US tradename | Criteria |
| $21 per dose | Experienced but not performed in USA [39] | With the intranasal measles vaccine [40] | Subacute sclerosing panencephalitis (0.7/ million) [41] | Serum sickness like arthralgia; febrile seizures [41] | Allergy to neomycin, gelatin, immunocompromised, pregnancy [41] | Chicken embryo fibroblast | Mumps, measles, rubella with varicella | Subcutaneous | M-M-R II | MMR |
| $0.15 per dose | Yes [21] | VAPP (1/million) only with OPV2; cVDPV also rare | VAPP fever, vomiting, diarrhea [42] | Allergy to vaccine component; in pregnancy, it should be used with caution [42] | Monkey kidney cells | bOPV (OPV1 and OPV3; not in use in USA) | Oral | Substituted by Ipol (IPV) in USA | OPV |
| $2–3 per dose worldwide; intravesicular use around $160 in USA [43] | Experienced but not performed in USA [44] | Yes [45] | BCG osteitis [46] | Disseminated disease in immunosuppressed [46] | Immunosuppression, allergy to component of vaccine, active tuberculosis [46] | Surface pellicle on synthetic medium [47] | Not administered as a combination vaccine in USA | Percutaneous, intravesicular | BCG vaccine, TICE | BCG |
| $18.88 per dose | Yes [21] | Guillain-Barré syndrome (controversial) [48] | Flu-like syndrome, wheezing, nasal congestion [48] | Immunosuppression, allergy to component of vaccine, pregnancy [48] | Egg based | Not administered as a combination vaccine in USA | Intranasal | FluMist | Influenza |
| $97.50 per dose, $71.88 per dose (pentavalent) | Yes [21] | Intussusception [49] | Cough, runny nose, fever, vomiting [49] | History of uncorrected congenital gastrointestinal malformation, intussusception, hypersensitivity to component of vaccine, severe combined immunodeficiency disease [49] | Virus from calf and human mixed | Not administered as a combination vaccine in USA | Oral | Rotarix, RotaTeq | Rota-virus |
| $20–240 per dose | Limited evidence [50] | Transmission of virus, anaphylaxis [52] | Headache and injection site reactions [52] | History of anaphylactic reaction to component of the vaccine, immune suppression [52] | Use human cell strains | Not administered as a combination vaccine in USA | Subcutaneous | Zostavax (discontinued in USA) | Shingles |
| $109.26 per dose | Yes | No sufficient data | | | Use human cell strains | | | | Varivax | Varicella |

Abbreviations: BCG, Bacillus Calmette-Guérin; CSF, cerebrospinal fluid; cVDPV, circulating vaccine-derived poliovirus; IPV, inactivated polio vaccine; MMR, measles, mumps, rubella; OPV, oral polio vaccine; VAPP, vaccine-associated paralytic poliomyelitis.
PROPOSED MECHANISMS FOR THE NONSPECIFIC EFFECTS OF VACCINES

Live viral vaccines have been known to activate the innate immune system utilizing various pattern-recognition receptors, including Toll-like receptors (TLRs) and nucleotide binding oligomerization domain–containing protein 2 (NOD2). Live vaccines closely mimic natural infections and activate TLRs and NOD2, producing a stronger immune response when compared with nonlive vaccines [19–22]. Live vaccines can then confer immunity by activating immune effector cells, which neutralize viral replication, promote opsonophagocytosis of pathogens, activate the complement cascade, bind to active sites of toxins [21], or kill cells via direct contact or cytokine production. CD4+ T lymphocytes, activated by dendritic cells in response to vaccines, differentiate into T-helper subsets that have unique functions: T-helper (Th) 1 cells produce interferon (IFN)-γ, tumor necrosis factor (TNF), and interleukin (IL)-2 and protect against intracellular pathogens; Th17 effector cells protect mucosal surfaces and produce IL-17, IL-22, and IL-26; and Th2 cells mediate production of immunoglobulin (Ig) E via IL-4, IL-5, and IL-13 to protect against extracellular pathogens [21]. While antibodies produced from vaccination help prevent disease, the immune training by live vaccines is thought to decrease the severity of disease and the amount of damage to organic tissue, including mucosal surfaces, by reducing viral shedding and invasive pathogens, allowing for nonspecific protection against other pathogens. This effect was demonstrated by Upfill-Brown et al. (2017), a randomized controlled trial that found that OPV use was associated with decreased prevalence of *Shigella* and *E. coli* diarrhea among male children and of *Campylobacter jejuni* diarrhea among children of both sexes in Bangladesh [23].

In addition to promoting adaptive immunity, live vaccines provoke a reconfiguration of the innate immune cells by epigenetic manipulation of these cells, as seen with the BCG vaccine. Kleinnijenhuis et al. (2012) demonstrated that monogenic phenotype modification occurred at least 2 weeks after BCG vaccination in humans. The CD14+ monocyte population markedly increased after vaccination, with a positive associated change in CD11b and TLR 4 expression that was still present at 3 months postvaccination, mediated by PRR NOD2 by methylation of histone H3 at lysine 4 [20]. This led to a 2-fold increase in release of cytokines in response to nontargeted bacterial and fungal pathogens and an early enhanced antimicrobial capacity by the innate immune system [20]. Brook et al. (2020) demonstrated that BCG vaccination in neonatal mice was associated with marked improvement in survival during sepsis by utilizing emergency granulopoiesis as a potential protective mechanism [24]. Its mechanism is thought to be due to an increase in hematopoietic growth factors, such as granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin-1β, and interleukin-3,-4,-6, within a few hours after BCG vaccination [24]. Kavanagh et al. (2010) examined the effects of the attenuated pertussis vaccine BPZE1 on severity of pertussis infection in animal models. They found that attenuated BPZE1 was associated with reduced bronchial hyperreactivity and inflammatory infiltration of the airways compared with mice who were not immunized and challenged with a virulent pertussis strain [16]. BPZE1 reduced ovalbumin-induced IgE and increased IFN-gamma, suggesting predominant induction of Th1 rather than Th2 cells. Cauchi and Locht et al. (2018) proposed that BPZE1 offered heterologous protection against other respiratory pathogens, including influenza and RSV, by cross-reactive B and T cells. BPZE1 was associated with decreased death and lung colonization by *B. bronchiseptica* and reduced inflammation, neutrophil, and tissue damage in the lungs of mice. More importantly, BPZE1 protected against lymphocyte depletion and cytokine hyper-response, evidenced by decreased levels of IL-1β, IL-6, and granulocyte-macrophage colony-stimulating factor [18]. This effect may be mediated by the adenyate cyclase toxin (ACT) in PTX-deficient strains (a virulent factor important for transmission), inhibiting the expression of genes coding for proinflammatory cytokines IL-1β, TNF-α, and IL-8, hence opposing inflammatory responses [18]. These mechanisms may be the foundation of possible benefits against SARS-CoV-2, some examples of which are illustrated in Figures 1 and 2 and Table 2. A summary of the evidence of the non-specific effects of vaccines can be found in Table 3.

THE NONSPECIFIC EFFECT OF VACCINES AGAINST SARS-COV-2

SARS-CoV-2 is a complex virus that has mechanisms of invasion and evasion of the immune system we have yet to fully understand. It seems to provoke a dysregulated, hyper–immune response leading to severe disease. Arunachalam et al. (2020) proposed that COVID-19 infection impairs the innate immune cells in the peripheral blood by suppressing cytokine production through suppressed TLR stimulation [25]. In addition, SARS-CoV-2 has a N-terminal nonstructural protein 1, which suppresses host gene expression and shuts down parts of the innate immune system involved in antiviral defense, such as IFN-β [26]. Earlier studies of SARS-CoV showed that its papain-like protease inhibits the IRF3 pathway, eliciting a high IFN response as well as inhibiting pro-inflammatory cytokines in TLR3 and retinoic acid–inducible gene pathways (RIG-1) [26, 27]. It also antagonizes the signaling activity of TLR7 for production of interferon, IL-6, and IL-8 [27]. Qian Zhang et al. (2020) found that 3.5% of patients with severe COVID-19 pneumonia had defects at 8 of 13 loci involved in the TLR3 and IRF7 induction of type 1 IFNs, further arguing the importance of such pathways [28]. Therefore, SARS-CoV-2 causes a maladaptive innate immune system response that also affects adaptive immunity [29]. If an impairment of the innate immune system is critical to SARS-CoV-2’s transmission and infection, one may hypothesize that...
Figure 1. Proposed mechanism of viral interference induced by the nonspecific effects of vaccines. A, SARS-CoV-2 life cycle: SARS-CoV-2 uses ACE2 and TMPRSS2 receptors to gain entry into human mucosal cells. Upon entry, it replicates using viral proteases and viral RNA polymerase enzymes. Viral particles are assembled in the Golgi apparatus and exocytosed through the endoplasmic reticulum. B, Nonspecific viral interference: Viruses that induce a type I interferon response before infection can preemptively block viral replication in susceptible mucosal cells. As shown in this figure, polio virus can induce a type I interferon response that triggers an innate immune response in mucosal cells in an autocrine and paracrine fashion. Upon binding to the interferon receptor, IFN-alpha promotes production of antiviral ISGs. These ISGs block multiple steps of SARS-CoV-2 replication including entry, transcription, translation, and assembly, resulting in blocking of infection. Abbreviations: IFN, interferon; ISG, interferon-stimulating gene; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
priming the innate immune system before infection can offset infectivity or attenuate COVID-19 disease.

TLR3/TLR7 stimulation is implicated in the nonspecific effect of vaccines by changing cytokine profiles and favoring Th1 rather than Th2 production, which plays a more significant role in response to viral infections [19]. In theory, this stimulation would provoke early activation of the innate immune system, including dendritic cells, which are the main determinants of CD4 T+ cell differentiation [16]. A skewed differentiation toward Th1 cells can lead to higher activation of CD8 T+ cells, extrafollicular B-cell help, enhanced dendritic cell activation, and rapid effector memory T-cell responses in the periphery to assist in cytotoxic activity against viruses [21]. In addition, the production of IFN-gamma may be beneficial, as it has been known to antagonize fibrosis and tissue remodeling by Th2 in asthma cases, which may help in reducing pulmonary disease in severe COVID-19 disease [16]. “Lifelong” immunity from these vaccines may be conferred by high antibody responses due to antigen persistence, which could lead to production of enough mucosal IgG and IgA to protect mucosal surfaces against viral invasion, ultimately protecting [21] against parenchymal damage by viruses or secondary pathogens [30].

Benn et al. (2020) presented 6 principles of the vaccine paradigm based on assumptions and contradictions regarding the nonspecific effects of vaccines that might be useful in optimizing the use of such vaccines [31]. Principles such as “the most recent vaccination has the strongest nonspecific effects” lead us to hypothesize that even though SARS-CoV-2 suppresses TLR signaling, use of OPV or other live vaccines prophylactically before COVID infection could activate innate immunity via TLRs and prime the immune system for adaptive immunity in the case of subsequent infection with SARS-CoV-2. Though there is an effort by the WHO and UNICEF to withdraw OPV a year after wild polio virus eradication, the potential benefits of OPV regarding COVID-19 warrant prospective studies to assess the impact that OPV may have on decreasing the morbidity and mortality from COVID-19 worldwide. Given the high rates of morbidity and mortality from COVID-19 we have already experienced, it is vital to perform these studies immediately.
### Table 3: Summary of Evidence for the Nonspecific Effect of Vaccines

| Vaccine          | Effect                                                                 |
|------------------|------------------------------------------------------------------------|
| Oral polio virus | • Reduced days of diarrhea (P = .0025) and fewer episodes of *Shigella*/EIEC when compared with IPV in male infants [23]  |
|                  | • Reduction in detection of *Escherichia coli* in all infants [23]       |
|                  | • Lower admissions due to lower respiratory tract infections in vaccinated children [9] |
|                  | • OPV campaigns associated with significant decreases in mortality rate (MRR, 0.75), with additional doses associated with a reduction of 14% in mortality rate [8] |
| MMR              | • Lower admissions due to lower respiratory tract infections in vaccinated children [9] |
|                  | • A risk reduction of up to 35% in hospitalization due to infectious diseases in the second year of life in high-income countries [54] |
| BCG              | • Reduction in mortality of 3-fold in neonatal vaccinated boys [55] |
|                  | • BCG scar associated with lower mortality for children when compared with those without a scar (MR, 0.45; 95% CI, 0.21–0.98) [56] |
|                  | • BCG scar associated with a significant reduction in risk of death from malaria [56] |
|                  | • An increase of 10% in BCG index was associated with a mortality reduction of 10.4% in COVID-19 mortality [57] |
|                  | • Induces emergency granulopoiesis improving survival in neonatal mice during sepsis [24] |
| Influenza        | • Produces strong innate immune responses to provide indirect protection against RSV [19] |
| Monovalent measles | • Two doses were associated with an all-cause mortality reduction of 21%, when given before DTP vaccine in children 4.5–36 months of age [17] |
|                  | • Lower mortality among vaccinated children vs unvaccinated children (HR, 0.76; 95% CI, 0.63–0.91), especially for early vaccinated children [58] |
|                  | • Early vaccination was associated with a lower risk of hospital admission, particularly for respiratory infections [59] |

**Abbreviations:** BCG, Bacillus Calmette-Guérin; COVID-19, coronavirus disease 2019; DTP, diphtheria, tetanus, pertussis; EIEC, enteroinvasive *Escherichia coli*; HR, hazard ratio; IPV, inactivated polio vaccine; MRR, mortality rate; MRR, mortality rate ratio; OPV, oral polio vaccine.

*a* This table is not exhaustive of all available data in the literature for all live attenuated vaccines. It summarizes some of the data available that demonstrate the nonspecific effects of vaccines.
References

1. Centers for Disease Control and Prevention. Polio disease and poliovirus. Available at: https://www.cdc.gov/polio/poliocontamination/diseaseandvirus.htm. Accessed 23 October 2020.

2. Voroshilova MK. Potential use of nonpathogenic enteroviruses for control of human disease. Prog Med Virol 1989; 36:191–202.

3. Voroshilova MK. Enterovirus Infections of Man. Moscow: Medicina; 1979.

4. Terekhov SN, Stepanchuk VA. Acute respiratory diseases. Materials of the Institute of Microbiology and Epidemiology 1971: p.62–6.

5. Priyamani LS, Grinspoorn LE. Use of live enterovirus vaccines for urgent prophylaxis of influenza. In: Chumakov ed. Medical Virology, Moscow; 1973: 21-29-37.

6. Chumakov MP, Voroshilova MK, Antsupova AS, et al. Live enteroviral vaccines for the emergency nonspecific prevention of mass respiratory diseases during fall-winter epidemics of influenza and acute respiratory diseases [in Russian]. Zh Mikrobiol Epidemiol Immunobiol 1992; 11: 12-37-40.

7. Lund N, Andersen A, Hansen AS, et al. The effect of oral polio vaccine at birth on infant mortality: a randomized trial. Clin Infect Dis 2015; 61:1504–11.

8. Andersen A, Fisker AR, Nielsen S, et al. National immunization campaigns with oral polio vaccine may reduce all-cause mortality: an analysis of 13 years of demographic surveillance data from an urban African area. Clin Infect Dis 2021; 72:e596–603.

9. Sørup S, Stensballe LG, Krause TG, et al. Oral polio vaccination and hospital admissions with non-polio infections in Denmark: nationwide retrospective cohort study. Open Forum Infect Dis 2016; 3:XXX–XX.

10. Bardenheir BH, McNeill MM, Wodi AP, et al. Risk of nontargeted infectious disease hospitalizations among US children following inactivated and live vaccines, 2005–2014. Clin Infect Dis 2017; 65:729–37.

11. Higgins JP, Soares-Weiser K, López-López JA, et al. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ 2016; 355:i7178.

12. Higgins JPT, Soares-Weiser K, Reingold A. Systematic review of the non-specific effects of BCG, DTP and measles containing vaccines. 2014. Available at: https://www.who.int/immunization/sage/meetings/2014/april/3_NSE_Epidemiology_review_Report_to_SAGE_14_Mar_FINAL.pdf. Accessed 01 October 2020.

13. Sorup S, Stensballe LG, Krause TG, et al. Oral polio vaccination and hospital admissions with non-polio infections in Denmark: nationwide retrospective cohort study. Open Forum Infect Dis 2016; 3:XXX–XX.

14. Prentice S, Nassanga B, Webb EL, et al. Delayed BCG Study Team. BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial. Lancet Infect Dis 2021; 21:993–1003.

15. Kavanagh H, Noone C, Cahill E, et al. Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model. Clin Exp Allergy 2010; 40:933–41.

16. Aaby P, Martins CL, Bale C, et al. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG? Vaccine 2003; 21:2782–90.

17. Benn CS, Roth A, Garly ML, et al. BCG scarring and improved child survival: a combined analysis of studies of BCG scarring. J Intern Med 2020; 288:614–24.

18. Arunachalam PS, Wimmers F, Mok CKP, et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science 2020; 369:1210–20.

19. Thomas M, Buschauer R, Ameisheimer M, et al. Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science 2020; 369:1249–55.

20. Li S-W, Wang C-Y, You Y-J, et al. SARS coronavirus papain-like protease inhibits the TLR7/8 signaling pathway through removing Lys63-linked polyubiquitination of TANK and TRAF6. Int J Mol Sci 2016; 17:678.

21. Siegrist CA. 2—Vaccine immunology. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. London: W.B. Saunders; 2011: 13-1-14-32.

22. Uppill-Brown A, Tannushi M, Plattis-Mills JA, et al. Nonspecific effects of oral polio vaccine on diarrheal burden and etiology among Bangladeshi infants. Clin Infect Dis 2017; 65:414–9.

23. Brook B, Harbeson DJ, Shannon CP, et al. BCG vaccination–induced emergency granulopoiesis provides rapid protection from neonatal sepsis. Sci Trans Med 2020; 12:eaxa4517.
51. Levin MJ, Schmader KE, Pang L, et al. Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults. J Infect Dis 2016; 213:14–22.
52. Food and Drug Administration. ZOSTAVAX® (zoster vaccine live) package insert. Available at: https://www.fda.gov/media/82524/download. Accessed 10 February 2021.
53. Food and Drug Administration. VARI VAX® (varicella virus vaccine live) package insert. Available at: https://www.fda.gov/media/76000/download. Accessed 10 February 2021.
54. Sinzinger AX, Von Kries R, Stedler A, et al. Non-specific effects of MMR vaccines on infectious disease related hospitalizations during the second year of life in high-income countries: a systematic review and meta-analysis. Hum Vaccin Immunother 2020; 16:490–8.
55. Biering-Sorensen S, Jensen KI, Monterio L, et al. Rapid protective effects of early BCG on neonatal mortality among low birth weight boys: observations from randomized trials. J Infect Dis 2018; 217:759–66.
56. Roth A, Gustafson P, Nhaga A, et al. BCG vaccination scar associated with better childhood survival in Guinea-Bissau. Int J Epidemiol 2005; 34:540–7.
57. Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci U S A 2020; 117:17720–6.
58. Hansen JS, Thysen SM, Rodrigues A, et al. Is early measles vaccination associated with stronger survival benefits than later measles vaccination? BMC Public Health 2018; 18:984.
59. Martins CL, Benn CS, Andersen A, et al. A randomized trial of a standard dose of Edmonston-Zagreb measles vaccine given at 4.5 months of age: effect on total hospital admissions. J Infect Dis 2014; 209:1731–8.